CSL (OTCMKTS:CSLLY) Shares Gap Up – Time to Buy?

CSL Limited Sponsored ADR (OTCMKTS:CSLLY)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $23.95, but opened at $28.2350. CSL shares last traded at $27.99, with a volume of 37,269 shares trading hands.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CSLLY. Zacks Research raised CSL from a “strong sell” rating to a “hold” rating in a research report on Friday, August 7th. Jefferies Financial Group downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Friday, May 29th. Citigroup downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Finally, Canaccord Genuity Group downgraded shares of CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Five investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold”.

CSL Price Performance

The company has a current ratio of 2.57, a quick ratio of 1.15 and a debt-to-equity ratio of 0.51. The company’s 50 day moving average price is $21.57 and its 200-day moving average price is $27.03.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.